222 related articles for article (PubMed ID: 32672361)
1. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
Liu X; Liu D; Pan Y; Li Y
J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
Gioia F; Gomez-Lopez A; Alvarez ME; Gomez-García de la Pedrosa E; Martín-Davila P; Cuenca-Estrella M; Moreno S; Fortun J
Int J Infect Dis; 2020 Dec; 101():24-28. PubMed ID: 32937195
[TBL] [Abstract][Full Text] [Related]
3. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.
Brüggemann RJ; Middel-Baars V; de Lange DW; Colbers A; Girbes AR; Pickkers P; Swart EL
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872072
[TBL] [Abstract][Full Text] [Related]
5. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
7. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity.
Gil-Alonso S; Quindós G; Cantón E; Eraso E; Jauregizar N
Rev Iberoam Micol; 2019; 36(1):24-29. PubMed ID: 30837186
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
Kofla G; Ruhnke M
Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
[TBL] [Abstract][Full Text] [Related]
10. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
[TBL] [Abstract][Full Text] [Related]
11. Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an
Siopi M; Perlin DS; Arendrup MC; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495222
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of the three echinocandins in ICU patients.
Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
[TBL] [Abstract][Full Text] [Related]
14. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
Gumbo T
Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408
[TBL] [Abstract][Full Text] [Related]
15. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
18. A clinical review of echinocandins in pediatric patients.
VandenBussche HL; Van Loo DA
Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
